Point72 Asia Singapore Pte. Ltd. Makes New Investment in Delcath Systems, Inc. (NASDAQ:DCTH)

Point72 Asia Singapore Pte. Ltd. purchased a new stake in Delcath Systems, Inc. (NASDAQ:DCTH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 11,318 shares of the company’s stock, valued at approximately $102,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Riverwater Partners LLC acquired a new position in Delcath Systems in the third quarter valued at approximately $161,000. Cubist Systematic Strategies LLC acquired a new position in shares of Delcath Systems in the 2nd quarter valued at $370,000. Renaissance Technologies LLC purchased a new position in shares of Delcath Systems during the 2nd quarter worth $694,000. Marshall Wace LLP increased its position in shares of Delcath Systems by 7.0% during the 2nd quarter. Marshall Wace LLP now owns 92,731 shares of the company’s stock worth $776,000 after purchasing an additional 6,066 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in Delcath Systems in the 3rd quarter valued at about $808,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Stock Performance

Shares of DCTH opened at $11.48 on Friday. The stock has a market capitalization of $367.06 million, a PE ratio of -8.50 and a beta of 0.85. The company’s 50-day simple moving average is $10.11 and its 200-day simple moving average is $8.94. Delcath Systems, Inc. has a 1 year low of $2.60 and a 1 year high of $12.88.

Analysts Set New Price Targets

Several research analysts have weighed in on DCTH shares. StockNews.com raised shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of Delcath Systems in a research report on Monday, November 11th. Stephens reissued a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Delcath Systems has an average rating of “Moderate Buy” and a consensus target price of $21.50.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.